Expression of the CXCL12/SDF-1 chemokine receptor CXCR7 in human brain tumours

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 10, 2012, Pages 5281-5286

  Tang, Tian ^a   Xia, Qing Jie ^b   Chen, Jian Bin ^a   Xi, Ming Rong ^c   Lei, Ding ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c SICHUAN UNIVERSITY   (China)

Author keywords

Chemokine receptors; CXCR7; Hemangioblastoma; Neurilemmoma; Pituitary adenoma

Indexed keywords

EID: 84874006023     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.10.5281     Document Type: Article

References (38)

1. Bajetto A, Bonavia R, Barbero S, Florio T, Schettini G (2001). Chemokines and their receptors in the central nervous system. Front Neuroendocrinol, 22, 147-84.
2. Barbieri F, Bajetto A, Porcile C, et al (2006). CXC receptor and chemokine expression in human meningioma: SDF1/CXCR4 signaling activates ERK1/2 and stimulates meningioma cell proliferation. Ann N Y Acad Sci, 1090, 332-43.
3. Begley LA, MacDonald JW, Day ML, Macoska JA (2007). CXCL12 activates a robust transcriptional response in human prostate epithelial cells. J Biol Chem, 282, 26767-74.
4. Begley L, Monteleon C, Shah RB, Macdonald JW, Macoska JA (2005). CXCL12 over expression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in vitro. Aging Cell, 4, 291-8.
5. Burns JM, Summers BC, Wang Y, et al (2006). A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med, 203, 2201-13.
6. Calatozzolo C, Canazza A, Pollo B, et al (2011). Expression of the new CXCL12 receptor, CXCR7, in gliomas. Cancer Biol Ther, 11, 242-53.
7. Dai X, Tan Y, Cai S, et al (2011). The role of CXCR7 on the adhesion, proliferation and angiogenesis of endothelial progenitor cells. J Cell Mol Med, 15, 1299-309.
8. do Carmo A, Patricio I, Cruz MT, et al (2010). CXCL12/CXCR4 promotes motility and proliferation of glioma cells. Cancer Biol Ther, 9, 56-65.
9. Gebauer F, Tachezy M, Effenberger K, et al (2011). Prognostic impact of CXCR4 and CXCR7 expression in pancreatic adenocarcinoma. J Surg Oncol, 104, 140-5.
10. Goldmann T, Drömann D, Radtke J, et al (2008). CXCR7 transcription in human non-small cell lung cancer and tumor-free lung tissues; possible regulation upon chemotherapy. Virchows Arch, 452, 347-8.
11. Kumar R, Tripathi V, Ahmad M, et al (2012). CXCR7 mediated Gia independent activation of ERK and Akt promotes cell survival and chemotaxis in T cells. Cell Immunol, 272, 230-41.
12. Liang X, Shen D, Huang Y, et al (2007). Molecular pathology and CXCR4 expression in surgically excised retinal hemangioblastomas associated with von Hippel-Lindau disease. Ophthalmology, 114, 147-56.
13. Luker KE, Steele JM, Mihalko LA, Ray P, Luker GD (2010). Constitutive and chemokine-dependent internalization and recycling of CXCR7 in breast cancer cells to degrade chemokine ligands. Oncogene, 29, 4599-610.
14. 2+-dependent, cytosolic tyrosine kinase Pyk2. Ann N Y Acad Sci, 1090, 385-98.
15. Meijer J, Ogink J, Roos E (2008). Effect of the chemokine receptor CXCR7 on proliferation of carcinoma cells in vitro and in vivo. Br J Cancer, 99, 1493-501.
16. Meincke M, Tiwari S, Hattermann K, Kalthoff H, Mentlein R (2011). Near-infrared molecular imaging of tumors via chemokine receptors CXCR4 and CXCR7. Clin Exp Metastasis, 28, 713-20.
17. Miao Z, Luker KE, Summers BC, et al (2007). CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci U S A, 104, 15735-40.
18. Morita R, Sato K, Nakano M, et al (2011). Endothelial progenitor cells are associated with response to chemotherapy in human non-small-cell lung cancer. J Cancer Res Clin Oncol, 137, 1849-57.
19. Odemis V, Boosmann K, Heinen A, Küry P, Engele J (2010). CXCR7 is an active component of SDF-1 signalling in astrocytes and Schwann cells. J Cell Sci, 123, 1081-8.
20. Odemis V, Lipfert J, Kraft R, et al (2012). The presumed atypical chemokine receptor CXCR7 signals through G(i/o) proteins in primary rodent astrocytes and human glioma cells. Glia, 60, 372-81.
21. Perlin JR, Talbot WS (2007). Signals on the move: chemokine receptors and organogenesis in zebrafish. Sci STKE, 2007, 45.
22. Proost P, Mortier A, Loos T, et al (2007). Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration. Blood, 110, 37-44.
23. Raggo C, Ruhl R, McAllister S, et al (2005). Novel cellular genes essential for transformation of endothelial cells by kaposi's sarcoma-associated herpesvirus. Cancer Res, 65, 5084-95.
24. Reca R, Wysoczynski M, Yan J, Lambris JD, Ratajczak MZ (2006). The role of third complement component (C3) in homing of hematopoietic stem/progenitor cells into bone marrow. Adv Exp Med Biol, 586, 35-51.
25. Salmaggi A, Maderna E, Calatozzolo C, et al (2009). CXCL12, CXCR4 and CXCR7 expression in brain metastases. Cancer Biol Ther, 8, 1608-14.
26. Schönemeier B, Schulz S, Hoellt V, Stumm R (2008). Enhanced expression of the CXCL12/SDF-1 chemokine receptor CXCR7 after cerebral ischemia in the rat brain. J Neuroimmunol, 198, 39-45.
27. Schutyser E, Su Y, Yu Y, et al (2007). Hypoxia enhances CXCR4 expression in human microvascular endothelial cells and human melanoma cells. Eur Cytokine Netw, 18, 59-70.
28. Shim H, Lau SK, Devi S, et al (2006). Lower expression of CXCR4 in lymph node metastases than in primary breast cancers: potential regulation by ligand-dependent degradation and HIF-1alpha. Biochem Biophys Res Commun, 346, 252-8.
29. Singh RK, Lokeshwar BL (2011). The IL-8-regulated chemokine receptor CXCR7 stimulates EGFR signaling to promote prostate cancer growth. Cancer Res, 71, 3268-77.
30. Sun X, Cheng G, Hao M, et al (2010). CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev, 29, 709-22.
31. Tarnowski M, Grymula K, Liu R, et al (2010). Macrophage migration inhibitory factor is secreted by rhabdomyosarcoma cells, modulates tumor metastasis by binding to CXCR4 and CXCR7 receptors and inhibits recruitment of cancer-associated fibroblasts. Mol Cancer Res, 8, 1328-43.
32. Terasaki M, Sugita Y, Arakawa F, et al (2011). CXCL12/CXCR4 signaling in malignant brain tumors: a potential pharmacological therapeutic target. Brain Tumor Pathol, 28, 89-97.
33. Tseng D, Vasquez-Medrano DA, Brown JM (2011). Targeting SDF-1/CXCR4 to inhibit tumour vasculature for treatment of glioblastomas. Br J Cancer, 104, 1805-9.
34. Wang J, Shiozawa Y, Wang J, et al (2008). The role of CXCR7/ RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem, 283, 4283-94.
35. Wojakowski W, Tendera M, Zebzda A, et al (2006). Mobilization of CD34(+), CD117(+), CXCR4(+), c-met(+) stem cells is correlated with left ventricular ejection fraction and plasma NT-proBNP levels in patients with acute myocardial infarction. Eur Heart J, 27, 283-9.
36. Yoshida D, Nomura R, Teramoto A (2009). Signalling pathway mediated by CXCR7, an alternative chemokine receptor for stromal-cell derived factor-1a, in AtT20 mouse adrenocorticotrophic hormone-secreting pituitary adenoma cells. J Neuroendocrinol, 21, 481-8.
37. Yoshida D, Koketshu K, Nomura R, Teramoto A (2010). The CXCR4 antagonist AMD3100 suppresses hypoxia-mediated growth hormone production in GH3 rat pituitary adenoma cells. J Neurooncol, 100, 51-64.
38. Zheng K, Li HY, Su XL, et al (2010). Chemokine receptor CXCR7 regulates the invasion, angiogenesis and tumor growth of human hepatocellular carcinoma cells. J Exp Clin Cancer Res, 29, 31.